Effective therapeutic options for patients living with chronic pain are limited. The pain relieving effect of cannabinoids remains unclear. A systematic review of RCTs examining cannabinoids in treatment of chronic non-cancer pain was conducted according to the PRISMA statement update on the QUORUM guidelines for reporting systematic reviews that evaluate health care interventions. Cannabinoids studied included smoked cannabis, oromucosal extracts of cannabis based medicine, nabilone, dronabinol and a novel THC analog. Chronic non-cancer pain conditions included neuropathic pain, fibromyalgia, rheumatoid arthritis, and mixed chronic pain. Overall the quality of trials was excellent. Fifteen of the eighteen trials that met inclusion criteria demonstrated a significant analgesic effect of cannabinoid as compared to placebo, several reported significant improvements in sleep. There were no serious adverse effects. Adverse effects most commonly reported were generally well tolerated, mild to moderate in severity and led to withdrawal from the studies in only a few cases. Overall there is evidence that cannabinoids are safe and modestly effective in neuropathic pain with preliminary evidence of efficacy in fibromyalgia and rheumatoid arthritis. The context of the need for additional treatments for chronic pain is reviewed. Further large studies of longer duration examining specific cannabinoids in homogeneous populations are required.
Introduction
Chronic pain is common, debilitating with too few effective therapeutic options. Cannabinoids represent a relatively new pharmacological option as part of a multimodel treatment plan. With increasing knowledge of the endocannabinoid system [1] [2] [3] and compelling preclinical work supporting that cannabinoid agonists are analgesic [4, 5] there is increasing attention on their potential role in the management of pain [6] [7] [8] [9] . A previous systematic review done a decade ago identified the need for further randomized controlled trials (RCTs) evaluating cannabinoids in management of chronic pain indicating that there was insufficient evidence to introduce cannabinoids into widespread use for pain at that time [10] . A subsequent review identified a moderately analgesic effect but indicated this may be offset by potentially serious harms [11] . This conclusion of serious harms mentioned in the more recent review is not consistent with our clinical experience. In addition there have been a number of additional RCTs published since this review. We therefore conducted an updated systematic review examining RCTs of cannabinoids in management of chronic pain.
Materials and Methods

2.0
We followed the PRISMA update on the QUORUM statement guidelines for reporting systematic reviews that evaluate health care interventions [12] .
Systematic Search
A literature search was undertaken to retrieve Randomized Control Trials (RCT) on the efficacy of cannabinoids in the treatment for chronic pain. The databases searched were: PubMed, Embase, CINAHL (EBSCO), PsycInfo (EBSCO), The Cochrane Library (Wiley), ISI Web of Science, ABI Inform (Proquest), Dissertation Abstracts (Proquest), Academic Search Premier (EBSCO), Clinical Trials.gov, TrialsCentral.org, individual pharmaceutical company trials sites for Eli Lilly and GlaxoSmithKline, OAIster (OCLC), and Google Scholar. None of the searches was limited by language or date and were carried out between September 7 and October 7, 2010. The search retrieved all articles assigned the Medical Subject Headings (MeSH) Cannabis, Cannabinoids, Cannabidiol, Marijuana Smoking and Tetrahydrocannibinol as well as those assigned the Substance Name tetrahydrocannabinol-cannabidiol combination. To this set was added those articles containing any of the keywords cannabis, cannabinoid*, marijuana, marihuana, dronabinol or tetrahydrocannibinol. Members of this set containing the MeSH heading Pain or the title keyword "pain" were passed through the "Clinical Queries: therapy/narrow" filter to arrive at the final results set. For the pain aspect, the phrase "Chronic pain" along with title keyword "pain" was used to retrieve the relevant literature. We contacted authors of original reports to obtain additional information. Bibliographies of included articles were checked for additional references.
Inclusion and exclusion criteria
Included were RCTs comparing a cannabinoid with a placebo or active control group where the primary outcome was pain in subjects with chronic non-cancer pain. Relevant pain outcomes included any scale measuring pain for example the numeric rating scale for pain (NRS), visual analog scale for pain (VAS), the Neuropathy Pain Scale or the McGill Pain Scale. We excluded (a) trials with fewer than 10 participants, (b) trials reporting on acute or experimental pain or pain caused by cancer, (c) preclinical studies and (d) abstracts, letters and posters where the full study was not published.
Data extraction and validity scoring
One author (ML) did the initial screen of abstracts, retrieved reports and excluded articles that clearly did not meet the inclusion criteria. Both authors independently read the included articles and completed an assessment of the methodological validity using the modified 7-point, 4-item Oxford scale [13, 14] (Figure 1 ). After reading the complete articles it was clear that several additional papers did not meet inclusion criteria and these were excluded. Discrepancies on the quality assessment scale were resolved by discussion. Trials that did not include randomization were not included and a score of 1 on this item of the Oxford scale was required and the maximum score was seven.
Information about the specific diagnosis of pain, agent and doses used, pain outcomes, secondary outcomes (sleep, function, quality of life), summary measures, trial duration and adverse events was collected. Information on adverse events was collected regarding serious adverse events, drug related withdrawals and most frequently reported side effects. A serious adverse event according to Health Canada and ICH 1 guidance documents is defined as any event that results in death, is life threatening, requires prolonged hospitalization, results in persistent of significant disability or incapacity or results in congenital anomaly or birth defects [15] .
Data analysis
Quantitative meta-analysis with pooling of data from the eligible RCTs was proposed.
Results
Trial Flow
Eighty abstracts were identified of which 58 did not meet inclusion criteria on the initial review of records ( Fig 2) . Twenty two RCTs comparing a cannabinoid with either a placebo or active control group where pain was listed as an outcome were found and full text articles were reviewed, four further studies were excluded, two because pain was not the primary outcome (Zajicek), one because there were fewer than 10 participants in the study (Rintala). A further study was excluded because there were two studies reporting on what appeared to be the same group of participants (Salim, Karst) , in this case we included the first study in which the pain outcomes were reported (Karst) . References of the included trials were reviewed for additional trials meeting inclusion criteria. This revealed no further studies. Eighteen trials met the study criteria for inclusion. We did not retrieve any unpublished data. Given the different cannabinoids, regimens, clinical conditions, different follow up periods, and outcome measures used in these trials, pooling of data for meta-analysis was inappropriate. Results were therefore summarized qualitatively.
Primary Outcome -Efficacy
Eighteen trials published between 2003 and 2010 involving a total of 766 completed participants met inclusion criteria ( Table 1 ). The quality of the trials was very good with a mean score of 6.1 on the 7 point modified Oxford scale. The majority (fifteen trials) demonstrated a significant analgesic effect for the cannabinoid agent being investigated. Several trials also noted significant improvements in sleep [16] [17] [18] [19] .Treatment effects were generally modest, mean duration of treatment was 2.8 weeks (range 6 hours-6 weeks) and adverse events were mild and well tolerated.
Cannabis
Four trials examined smoked cannabis as compared with placebo; all examined populations with neuropathic pain, two involved neuropathic pain in HIV neuropathy [16, [20] [21] [22] . All four trials found a positive effect with no serious adverse effects. The median treatment duration was 8.5 days treatment (range 6 hours-14 days).
Oromucosal extracts of cannabis based medicine (CBM)
Seven placebo controlled trials examined CBM [17] [18] [19] [23] [24] [25] . Five examined participants with neuropathic pain, one rheumatoid arthritis and one a mixed group of people with chronic pain many of whom had neuropathic pain. Six of the seven trials demonstrated a positive analgesic effect. Of note in the one trial examining pain in rheumatoid arthritis, the CBM was associated with a significant decrease in disease activity as measured by the 28 joint disease activity score (DAS28) [18] .
Nabilone
Four trials studied nabilone [26] [27] [28] [29] . Three of these trials were placebo controlled and found a significant analgesic effect in spinal pain [29] , fibromylagia [27] and spasticity related pain [28] . The fourth compared a daily dose of nabilone 2 mg with dihydrocodeine 240 mg in neuropathic pain. Mean baseline pain was 69.6 mm on the 100 mm VAS and dropped to 59.93 mm for participants taking nabilone and 58.58 mm for those taking dihydrocodeine [26].
Dronabinol
Two trials involved dronabinol. The earlier trial found that dronabinol 10 mg per day led to significant reduction in central pain in multiple sclerosis [30] , a subsequent trial found that dronabinol at both 10 and 20 mg per day led to significantly greater analgesia and better relief than placebo as adjuvant treatment for a group of participants with mixed diagnoses of chronic pain on opioid therapy [31] .
THC-11-oic acid analog (CT-3 or ajulemic acid)
Two studies reported on various aspects of this trial examining ajulemic acid in a group of participants with neuropathic pain with hyperalgesia or allodynia [32, 33] . 19 of 21 completed the trial. It was found that ajulemic acid led to significant improvements in pain intensity at 3 hours but no difference at 8 hours as compared with placebo.
Secondary Outcome -Level of Function
Several trials included secondary outcome measures relating to level of function. Two trials examining cannabis based medicines included the Pain Disability Index (PDI) [19, 25] . Nurmikko found that 6 of 7 functional areas assessed by the PDI demonstrated significant improvement on CBM (-5.61) as compared with placebo (0.24) (estimated mean difference-5.85, P=0.003) in 125 participants with neuropathic pain while Berman noted no significant difference from placebo in 48 participants with central pain from brachial plexus avulsion. Two studies included the Barthel index for activities of daily living (ADL) [23, 28] and noted no significant improvement in ADLs with nabilone for spasticity related pain [28] or with CBMs for multiple sclerosis [23] . In one trial examining nabilone in treatment of fibromyalgia the FIQ [34] demonstrated significant improvement as compared to placebo. This measure includes a number of questions regarding function in several areas including shopping, meal preparation, ability to do laundry, vacuum, climb stairs and ability to work. The FIQ also includes questions relating to pain, fatigue, stiffness and mood. The total scores presented in this study were not presented separately so the reader cannot be certain; however given that the majority of questions relate to function it is likely that there were some improvements in function.
3.4Drug related adverse effects
There were no serious adverse events according to the Health Canada definition described above and in Table 1 , The most common adverse events consisted of sedation, dizziness, dry mouth, nausea and disturbances in concentration. Other adverse events included poor coordination, ataxia, headache, paranoid thinking, agitation, dissociation, euphoria and dysphoria. Adverse effects were generally described as well tolerated, transient or mild to moderate and not leading to withdrawal from the study. This is a significant difference from the withdrawal rates seen in studies of other analgesics such as opioids where the rates of abandoning treatment are in the range of 33% [35] . Except where specifically noted in the Table there was no specific mention of whether adverse effects caused limitations in function. The most severe treatment related event in the entire sample was a fractured leg related to a fall that was thought to be related to dizziness [29] . Details regarding specific trials are presented in Table 1 .
Discussion
Efficacy and harm
All of the trials included in this review were conducted since 2003; no trials prior to this date satisfied our inclusion criteria. This review has identified 18 trials that taken together have demonstrated a modest analgesic effect in chronic non-cancer pain; 15 of these were in neuropathic pain with 5 in other types of pain 1 in fibromyalgia, 1 in rheumatoid arthritis 1 as an adjunct to opioids in patients with mixed chronic pain and 2 in mixed chronic pain. Several trials reported significant improvements in sleep. There were no serious adverse events. Drug related adverse effects were generally described as well tolerated, transient or mild to moderate and most commonly consisted of sedation, dizziness, dry mouth, nausea and disturbances in concentration.
Limitations
The main limitations to our findings are short trial duration, small sample sizes and modest effect sizes. Thus there is a need for larger trials and for longer duration so that efficacy and safety, including potential for abuse, can be examined over the long term in a greater number of patients. It is also important to recognize that cannabinoids may only reduce pain intensity to a modest degree. It remains for the patients to decide whether this is clinically meaningful.
The context of chronic pain
Pain is poorly managed throughout the world. Eighty percent of the world population has no or insufficient access to treatment for moderate to severe pain [36] . Chronic pain affects approximately one in five people in the developed world [37-41] and two in five in less well resourced countries [42] . Children are not spared [43, 44] and the prevalence increases with age [38, 45] . The magnitude of the problem is increasing. Many people with diseases such as cancer, HIV and cardiovascular disease are now surviving their acute illness with resultant increase in quantity of life, but in many cases, poor quality of life due to persistent pain caused either by the ongoing illness or nerve damage caused by the disease after resolution or cure of the disease. In many cases the pain is also caused by the treatments such as surgery, chemotherapy or radiotherapy needed to treat the disease [46] [47] [48] .
Chronic pain is associated with the worst quality of life as compared with other chronic diseases such as chronic heart, lung or kidney disease [45] . Chronic pain is associated with double the risk of suicide as compared to those living with no chronic pain [49] ,.
In this context, patients living with chronic pain require improved access to care and additional therapeutic options. Given that this systematic review has identified 18 RCTs demonstrating a modest analgesic effect of cannabinoids in chronic pain that are safe, we conclude that it is reasonable to consider cannabinoids as a treatment option in the management of chronic neuropathic pain with evidence of efficacy in other types of chronic pain such as fibromyalgia and rheumatoid arthritis as well. Of special importance is the fact that two of the trials examining smoked cannabis [20, 21] demonstrated a significant analgesic effect in HIV neuropathy, a type of pain that has been notoriously resistant to other treatments normally used for neuropathic pain [47] . In the trial examining cannabis based medicines in rheumatoid arthritis a significant reduction in disease activity was also noted, this is consistent with pre-clinical work demonstrating that cannabinoids are anti-inflammatory [50, 51] .
Conclusion
In conclusion this systematic review of 18 recent good quality randomized trials demonstrates that cannabinoids are a modestly effective and safe treatment option for chronic non-cancer (predominantly neuropathic) pain. Given the prevalence of chronic pain, its impact on function and the paucity of effective therapeutic interventions, additional treatment options are urgently needed. More large-scale trials of longer duration reporting on pain and level of function are required. 
